Compare Digital Realty Trust, Inc. (DLR) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Digital Realty Trust, Inc. vs Incyte Corporation — how do they compare? Digital Realty Trust, Inc. trades at $196.05 (market cap $70.61B), while Incyte Corporation trades at $120.65 (market cap $24.54B). The key difference: Digital Realty Trust, Inc. is far larger — about 2.9× Incyte Corporation's market cap, and Digital Realty Trust, Inc. pays a 2.56% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| DLR | INCY | |
|---|---|---|
Market Cap | $70.61B | $24.54B |
Sector | Real Estate | Health |
52-Week High | $203.91 | $129.93 |
52-Week Low | $147.93 | $81.61 |
Enterprise Value | $89.32B | $20.04B |
Dividend Yield | 2.56% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Digital Realty (DLR) trades at $191.3, down 1.29% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong Q2 2026 earnings, beating FFO estimates and raising full-year guidance, driven by record leasing and robust AI-driven data center demand. Revenue grew to $6.11B in 2025, with net income margin at 11.8%, though valuation ratios like P/E of 241.53 appear elevated. A dividend of $1.22 per share was declared for H1 2026.
DLR's outlook is positive due to strong AI infrastructure demand and raised guidance, but high valuation and significant capital expenditures pose risks. Analyst consensus is bullish with a $216.56 price target, though investors should monitor execution on growth targets and debt levels amid expanding investments.
INCY trades at $121.55, near its consensus price target of $122.82, with a bullish technical signal and strong recent earnings beats. Revenue grew to $5.14B in 2025, with net income surging to $1.29B, reflecting robust profitability. The company raised its 2026 revenue outlook following strong Q2 results and positive developments like EU approval for Opzelura.
Outlook is positive with solid fundamentals and analyst support, though risks include competitive pressures and reliance on key products. The stock offers growth potential but requires monitoring of execution and market conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Digital Realty Trust, Inc.
Digital Realty owns and operates nearly 300 data centers worldwide. It has more than 35 million rentable square feet across five continents. Digital's offerings range from retail co-location, where an enterprise may rent a single cabinet and rely on Digital to provide all the accommodations, to cold shells, where hyperscale cloud service providers can simply rent much, or all, of a barren, power-connected building. In recent years, Digital Realty has de-emphasized cold shells and now primarily provides higher-level service to tenants, which outsource their related IT needs to Digital. Digital Realty has also moved more into the co-location business, increasingly serving enterprises and facilitating network connections. Digital Realty operates as a real estate investment trust.
Read more on DLR →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
